Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X about a paper by A. Strahan et al. published on ESMO Journals:
“Practice affirming. Adjuvant capecitabine for residual disease after adjuvant chemo improves outcomes.
Reassuring this is true in a real world data set and not just the CREATE-X trial. Interestingly only half receive adjuvant therapy.”
Title: Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
Authors: A. Strahan, Q. Jin, A.S. Raghavendra, D.B. Zakon, M. Grimm, M.E. Hughes, M. Cherian, J. Vincuilla, T. Parker, P. Tarantino, K.C.C. Johnson, E.A. Mittendorf, T.A. King, V. Valero, D. Tripathy, S.M. Tolaney, N. Tayob, N.U. Lin, D.G. Stover, C.H. Barcenas, A.C. Garrido-Castro
Read the full article.
More posts featuring Erika Hamilton on OncoDaily.